<DOC>
	<DOCNO>NCT02765633</DOCNO>
	<brief_summary>The purpose study assess PK/PD safety profile cangrelor neonatal subject risk thrombosis .</brief_summary>
	<brief_title>Cangrelor Neonatal PK/PD Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Cangrelor</mesh_term>
	<criteria>Inclusion criterion : 1 . Males females congenital heart disease , range age birth 28 day life 2 . Postoperative neonatal cardiac subject placement systemictopulmonary artery palliative shunt , right ventricle pulmonary artery palliative shunt , ductus arteriosus stent risk thrombotic event repair structural congenital heart disease . 3 . Written inform consent parent/legal guardian 4 . Life expectancy least 15 day study entry Subjects exclude study follow exclusion criterion apply : 1 . History intracerebral bleed ( confirm US head prior surgery ) , cerebral arteriovenous malformation , prior bleed neurological deficit 2 . Gastrointestinal urinary bleeding 3 . Cerebrovascular accident cerebrovascular accident residual neurological deficit 4 . Known congenital acquire bleed clot disorder 5 . Weight le 2.5 kg 6 . Adjusted gestational age le 37 week 7 . Platelet count le 100,000 cells/µL 8 . Chest and/or mediastinal tube blood output great 3 mL/kg/hr time cangrelor administration 9 . Subjects evidence severe hepatic renal failure [ aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) great three time normal age total bilirubin great 20 mg/dL ; creatinine great 2 time normal upper limit ] 10 . Known allergy cangrelor know sensitivity component cangrelor 11 . Any condition investigator 's opinion would constitute contraindication participation study cause inability comply study requirement 12 . Participation another investigational therapeutic drug investigational therapeutic device trial within 30 day start study 13 . Subjects receive warfarin ( Coumadin® ) therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>28 Days</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>